TP53 mutation landscape and patient survival in oral squamous cell carcinoma.
Summary
This study investigated the TP53 mutation landscape in oral squamous cell carcinoma (OSCC) and its association with patient survival. Using next-generation sequencing on 124 samples, pathogenic TP53 mutations were detected in 65% of patients, encompassing 75 distinct variant patterns. Patients harboring these mutations exhibited significantly shorter cancer-specific survival, particularly those with advanced-stage (III/IV) disease. Truncating or splice mutations were associated with an even worse prognosis. These findings highlight the importance of TP53-based molecular classification for developing novel precision strategies against OSCC.
Analysis
🔴 CLINIQUE : This retrospective study of 124 patients demonstrates that pathogenic TP53 mutations are a significant prognostic biomarker in OSCC, associated with shorter cancer-specific survival (HR = 3.70). This association is particularly pronounced in advanced stages (III/IV). These findings justify the development of precision strategies based on TP53 status, with a potential clinical impact in 3-5 years for patient stratification and therapeutic guidance. 🟢 BIOMOL : The comprehensive characterization of the TP53 mutational landscape using next-generation sequencing (NGS) on surgical specimens revealed a high diversity of variants (75 different types). This approach led to the discovery that truncating and splice mutations are associated with a particularly poor prognosis, which could lead to future clinical tests for more refined molecular classification. 🔵 BIOINFO : The study utilized genomic databases such as OncoKB and ClinVar to define the pathogenicity of TP53 mutations. This application of existing bioinformatics resources is crucial for the clinical interpretation of variants and could be integrated into clinical workflows for variant review and therapeutic decision-making.